// App-Quantinova.ai

P042/P042 : Effectiveness, Safety and Patient-reported Outcomes of Ofatumumab in Relapsing Multiple Sclerosis Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design

Researchers

Presenter

  • M. Craner

Principal Investigators

  • R. Bove

  • D. Langdon

  • D. Detka

  • J. Ricart

  • A. Mistry

  • P. Maxwell

  • C. B. Pisal

  • P. Desireddy

  • D. Stoneman

  • M. Ziehn

  • T. Derfuss

Medical Centers

  • John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, UNITED KINGDOM

  • University of California, San Francisco, San Francisco, CA

  • Royal Holloway, University of London, London, UNITED KINGDOM

  • Novartis Pharma AG, Basel, SWITZERLAND

  • Novartis Farmacéutica, Barcelona, SPAIN

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

Locations

  • United Kingdom

  • United States

  • Switzerland

  • Spain

  • India

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

  • Depression

  • Anxiety

Biomarkers

  • Glial fibrillary acidic protein

  • Neurofilament-light chain

Drug/Treatment

  • Dimethyl fumarate

  • Fingolimod

  • ofatumumab Intravenous

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved